Home ›
Lung Cancer Trials ›
NCT07169552
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS ≥1%)
Trial Details
NCT ID NCT07169552
Phase PHASE2
Sponsor HC Biopharma Inc.
Status RECRUITING
Cancer Type Lung Cancer
Interventions
Locations (sample) Shanghai, Shanghai Municipality, China|31.22222,121.45806
Key Eligibility Criteria
1\. Voluntarily participate in the study, communicate well with investigators, understand and voluntarily complete the study process according to t… 2\. Male or female, aged ≥ 18 years at the time of signing the informed consent form. 3\. Histologically or cytologically confirmed locally advanced or metastatic (stage IIIb\~IV) NSCLC (United States Cancer Confederation \[AJCC\] 8t… 4\. Not previously receiving systemic therapy for locally advanced or metastatic NSCLC; not allowed if the last dose of prior treatment is \<6 mont…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →